Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Glen Santangelo with Credit Suisse.
Glen Santangelo - Credit Suisse
I just have two quick questions. In your opening remarks you kind of suggested that you saw revenues in your generic program up double digits. I am kind of curious, is that really just a function of the patent expirations, or are you seeing some increased penetration within your customer base in terms of your generic book of business? What I am really trying to get a sense for is as the generic fill rate climbs is anybody trying to purchase generics on their own or are your clients basically coming to you more with the help of your generic One Source program.
David Yost
I am glad to answer your question. It is a function of three things. It is a function of new products increased utilization, but increased penetration as well. I would say, to answer your question specifically about our customers, we find our customers relying on us more and more for their generic decisions and it is a great value that we bring to them by searching the market for the best value in generics and in bringing that to them. Generics continue to be a big emphasis for us and it is definitely getting some traction. Thank you for the question.
Glen Santangelo - Credit Suisse
Dave, maybe I could ask a follow up question on Longs. Now that the CVS merger is kind of closed, I think you have some contract protection through some point in 2010 or 2011. Have you really had any kind of conversations with Longs kind of post that deal closing and do you have any sense for, kind of, what they may be thinking?
David Yost
We really haven’t Glen. I mean our focus at this point has been on the integration. Assisting them, assisting CVS with the integration of Longs. That is our primary focus and we really don’t have anything new to report on the status of our contract or Long ongoing relationship.
Operator
Your next question comes from John Ransom with Raymond James.
John Ransom - Raymond James
Some of the early data out there suggests a little bit of a rebound in prescription volumes in January. Do you think this is a head fake or a couple of weeks of bad data or are you seeing any signs that the market might be stabilizing to rebounding?
- To read the full transcript on Seeking Alpha, click here »
